Positive Data of T-Cell-Therapy
Hørsholm - The Danish biotech company T-cellic A/S demonstrated that their specific T-cells can act as carriers of compounds in the localization and treatment of cancer tumours and metastases, when highly statistically significant early data was presented at the ASCO meeting. “We have been able to locate tumours with a diameter of less than 10 mm, using the combined PET/MR imaging technology in our mouse melanoma model. This indicates that our pre-clinical proof of concept with T-cell-guided Boron Neutron Capture Therapy using our novel proprietary nano-pharmaceutical is within reach,” says Jan Trøst Jørgensen, VP of Research & Development of T-cellic. T-cells labeled with an imaging agent have been adoptively transferred to mice of a well-established mouse model bearing implanted melanoma tumours. A subsequent image analysis of PET/MR scans demonstrated the T-cell migration to the tumour sites. Results showed a clear homing of the transferred cells to the tumours. T-cellic's research partners at Århus University concluded that these specific, migrating T-cells could be employed in a new form of therapy as carriers of toxic substances to tumours, since these studies show that tumour-specific T-cells home to subcutaneous tumours in substantial numbers.